Invest News DetailPRNet – Revnue of Zentiva, a company headquartered in Czech Republic which entered the Turkish market via acquiring 75% of the shares in one of the companies of Eczacıbasi that is specialized in generic pharmaceuticals production, hit $600 million with a 32% increase. Jiri Michal, CEO of Zentiva, said, "Our operations in Türkiye have substantially compensated for our low performance in Romania and Czech Republic."